CVN-058 / Cerevance - LARVOL DELTA

Mismatch Negativity as an Index of Target Engagement for Excitation/Inhibition-Based Treatment Development: A Double-Blind, Placebo-Controlled, R Single-Dose Cross-Over Study of the Serotonin Type-3 Receptor Antagonist CVN058 (ACNP 2021) - "These results show MMN to be a sensitive target engagement biomarker for 5-HT3R, and support the potential utility of CVN058 in correcting the excitatory/inhibitory imbalance in schizophrenia."

Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. (PubMed, Neuropsychopharmacology) - "There were no clinically significant treatment related adverse effects. These results show MMN to be a sensitive target engagement biomarker for 5-HTR, and support the potential utility of CVN058 in correcting the excitatory/inhibitory imbalance in schizophrenia."

Clinical • Journal • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

CVN058 Effect on Mismatch Negativity in Schizophrenics (clinicaltrials.gov) - P1; N=20; Completed; Sponsor: Cerevance Alpha, Inc.; Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Psychiatry • Schizophrenia

[VIRTUAL] CVN058, a 5-HT3 Receptor Antagonist, Shows Acute, Dose Dependent Improvement of Mismatch Negativity in a Double-Blind, Placebo-Controlled, Single Dose Cross-Over Study in Schizophrenia and Schizoaffective Disorder (SOBP 2021) - No abstract available

Clinical • CNS Disorders • Psychiatry • Schizophrenia

[VIRTUAL] 5-HT Type 3 Receptors Antagonists in Schizophrenia and Depression (SOBP 2021) - "CVN058 shows excellent drug-like properties, is highly selective and brain penetrant in rodent species; therefore, it represents a good candidate to assess the role of 5HTR3 antagonism as a potential treatment for CIAS. Funding Source Unfunded"

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Mood Disorders • Psychiatry • Schizophrenia

[VIRTUAL] Identification of CVN058, a Novel Brain penetrant, Selective 5-HT3 Receptor Antagonist That Shows Efficacy in Pre-Clinical Cognition Models (SOBP 2021) - No abstract available

Preclinical • CNS Disorders

A New Drug for Schizophrenia-Related Cognitive Impairments? (Psychiatric Times) - "Significant cognitive impairments often accompany schizophrenia. In this Mental Health Minute, Dr Kantrowitz discusses a recent trial of CVN058, a drug that may reduce cognitive impairments in individuals with schizophrenia. The trial recruited 19 men and women with schizophrenia, giving them a single dose of either CVN058 or a placebo at each study visit. In this video, Dr Kantrowitz reveals the statistically significant results."

Video • Schizophrenia

Cerevance’s CVN058 Achieves Primary Endpoint in Phase Ib Schizophrenia Cognition Study (GlobeNewswire) - P1b, N=20; NCT03669250; Sponsor: Cerevance Alpha, Inc.; "Cerevance...today announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia (CIAS). 'A single dose of CVN058 elicited a statistically significant improvement in mismatch negativity (MMN), an auditory evoked potential generated in the cerebral cortex that is typically impaired in schizophrenics,' noted David H. Margolin, M.D., Ph.D., senior vice president of clinical and translational medicine at Cerevance."

P1 data • CNS Disorders • Schizophrenia

CVN058 Effect on Mismatch Negativity in Schizophrenics (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Cerevance Alpha, Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: May 2020 ➔ Aug 2020

Clinical • Enrollment closed • Trial completion date • CNS Disorders • Schizophrenia

CVN058 Effect on Mismatch Negativity in Schizophrenics (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Cerevance Alpha, Inc.; Trial completion date: Sep 2019 ➔ May 2020; Trial primary completion date: Aug 2019 ➔ Mar 2020

Clinical • Trial completion date • Trial primary completion date